Elmer Video

Clininal Study Reporting Guidelines


Randomized trials (CONSORT)
Observational studies (STROBE)
Systematic reviews (PRISMA)
Case reports (CARE)
Qualitative research (SRQR
Diagnostic / prognostic studies (STARD)
Quality improvement studies (SQUIRE)
Economic evaluations (CHEERS)  
Animal pre-clinical studies (ARRIVE)
Study protocols (SPIRIT)
Clinical practice guidelines (AGREE)


Publishing Policy

Elmer Press Publishing Policies, and Guidelines to follow, click for details......


Our journals are open access, which means all the contents of the journals are accessible freely to all viewers from every part of the world as long as they have internet accessibility, More...

Contact Us


Elmer Press Inc.
9225 Leslie Street, Suite 201
Richmond Hill
Ontario, L4B 3H6
Tel:  647-671-2629 (alternative email)

Publishing News

May 11, 2022

Journals Ranking 

World Journal of Oncology

Scopus Scimago Journal Rank (2021): 116/340 (Oncology), Q2

Cardiology Research

Scopus Scimago Journal Rank (2021): 130/356(Cardiology and Cardiovascular Medicine), Q2


March 30, 2022

Sedentary Lifestyle Attenuates Positive Metabolic Effect of Regular Physical Exercise
By Anna S. Isayeva et al. Journal of Endocrinology and Metabolism, Published Online First, 2022

The aim of the study was to evaluate the influence of the duration of sedentary time on blood lipids and anthropometric parameters in people practicing resistance training in leisure time. Our study included 213 subjects without any history of cardiovascular disease. The target group (169 subjects) had at least two 90-min sessions of resistance training per week for at least 12 months prior to study commencing.  Read More.... 

March 22, 2022

Statin Use in Patients With Chronic Liver Disease and Cirrhosis: Current Evidence and Future Directions 
By Malek Kreidieh et al. Gastroenterology Research, Vol. 15, No. 1, Feb 2022

Chronic liver disease (CLD) and its complications constitute a significant cause of mortality and morbidity worldwide. Most deaths are secondary to the decompensation of cirrhosis and evolution of portal hypertension (PHTN). Since disease progression reversal is hardly attainable after decompensated cirrhosis develops, it is essential to intervene early with a therapeutic agent or regimen that could prevent or slow disease evolution.  Read More....